• 1
    Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:24132446.
  • 2
    Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to JNC VI risk stratification. Hypertension. 2000;35:539543.
  • 3
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • 4
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:25602572.
  • 5
    McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care. 2002;25:718723.
  • 6
    Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:26612667.
  • 7
    Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276:18861892.
  • 8
    Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) trial. Lancet. 1998;351:17551762.
  • 9
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757764.
  • 10
    Tuomilehto J, Rastenyte D, Birkenhager WH, et al. for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677684.
  • 11
    United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703713.
  • 12
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253259.
  • 13
    Lindholm LH, Ibsen H, Devereux RB, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:10041010.
  • 14
    Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in patients with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committee Working Group. Am J Kidney Dis. 2000;36:646661.
  • 15
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): a prospective observational study. BMJ. 2000;321:412419.
  • 16
    Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl 2)B54B64.
  • 17
    Kario K, Pickering TG. Modification of high blood pressure after myocardial infarction. Med Clin North Am. 2000;84:121.
  • 18
    Eichhorn EJ, Young JB. Optimizing the use of beta-blockers in the effective treatment and management of heart failure: a case study approach. Am J Med. 2001;110(suppl 5A):11S20S.
  • 19
    Pyorala K, Pedersen TR, Kjekhus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care. 1997;20:614620.
  • 20
    Koskinen P, Manattari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820825.
  • 21
    Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21:641648.
  • 22
    Goldberg RB, Mellies JM, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98:25132519.
  • 23
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:24862497.
  • 24
    Larme AC, Pugh JA. Attitudes of primary care providers toward diabetes: barriers to guideline implementation. Diabetes Care. 1998;21:13911396.
  • 25
    Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162:413420.
  • 26
    Clark CM Jr, Snyder JW, Meek RL, et al. A systematic approach to risk stratification and intervention within a managed care environment improves diabetes outcomes and patient satisfaction. Diabetes Care. 2001;24:10791086.
  • 27
    Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:14581465.
  • 28
    Berwick DM. A user's manual for the IOMs ‘Quality Chasm’ report. Health Aff. 2002;21:8090.
  • 29
    Giese M, Lackland DT, Egan BM. The hypertension initiative of South Carolina. Promoting cardiovascular health through better blood pressure control. J S C Med Assoc. 2001;97:5762.
  • 30
    Egan BM, Lackland DT, Basile JN. American Society of Hypertension regional chapters: leveraging the impact of the clinical hypertension specialist in the local community. Am J Hypertens. 2002;15:372379.
  • 31
    Egan BM, Lackland DT. Strategies of prevention and the importance of public health and community programs. Ethn Dis. 1998;8:143154.
  • 32
    Siegel D, Lopez J, Meier J, et al. Changes in the pharmacologic treatment of hypertension in the Department of Veterans Affairs 1997–1999: decreased use of calcium antagonists and increased use of beta-blockers and thiazide diuretics. Am J Hypertens. 2001;14:957962.
  • 33
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 34
    Materson BJ, Reda DJ, Cushman WC, et al. Results of combination anti-hypertensive therapy after failure of each of the components. J Hum Hypertens. 1995;9:791796.
  • 35
    Weir MR, Maibach EW, Bakris GL, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000;160:481490.
  • 36
    Singer GM, Izhar M, Black HR. Goal-oriented hypertension management. Translating clinical trials to practice. Hypertension. 2002;40:464469.
  • 37
    Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care. 2001;24:454459.